Expert Perspective

Dispelling Common Headache Myths


 

Patients may be familiar with several myths and have misconceptions about headaches and migraine, which often arise due to a combination of factors, including limited understanding of the conditions, cultural beliefs, misinformation, and the complex nature of headaches. Being aware of these myths and seeking accurate information help patients to better understand and manage their headaches.

Myth: Migraine Is the Most Common Type of Headache

This is not true. The most common type of headache is tension-type headache , and it's the kind of headache that almost everyone has from time to time. Between 40% and 80% of the US population have had some form of tension-type headache, but only about 13% of the adult population have migraine. Stress can make muscles in the head and neck tense and knotted, and these muscles can be the source of a tension-type headache. Sometimes these headaches are not at all related to muscles or stress. Neck position may also be a factor. Pain from this type of headache is usually felt on both sides of the head and presents more often as steady, dull pressure or pain that’s usually mild to moderate in intensity. The pain can be in the forehead and eyes or further back in the head. Tension-type headaches are not usually associated with nausea, vomiting, or light and sound sensitivity.

When a tension-type headache is really severe, patients could consider this headache a migraine . Clinicians can easily distinguish tension-type headache from migraine, which often presents on one side of the head, with moderate or severe intensity, is throbbing, and is associated with nausea, vomiting, and light and sound sensitivity.

Myth: Only Adults Get Headaches

False. Headaches aren’t experienced just by adults. However, unlike adults, children find it harder to explain their headaches. It is true that adults have more migraines than children; children’s migraines are often hard for doctors to recognize. A 6- to 9-year-old child is 50% less likely than an adult to have migraine, and their attacks are more often bilateral, are shorter, and respond to sleep quickly.

Myth: Migraines Are Just Really Bad Headaches

False. They are bad, but that is only a small part of the story. A migraine attack is different from other headaches ; they actually are 1 of the 3 primary headache disorders, along with tension-type headache and cluster headache. A moderate or severe headache is one of the many characteristics of migraine, and some patients do not even have a headache during a migraine attack. Migraine is an inherited disease of the brain and other parts of the nervous system and can feel much worse than a normal headache. During a migraine attack, the brain does not process sensory data, such as lights, sound, or touch, properly. Patients might even experience visual, sensory, or speech problems (ie, auras) and sometime see flashing lights or zigzag lines that blink on and off or blind spots in their vision. Patients with migraine are often nauseated and severely bothered by light, sound, and even smells. Migraine headaches can last between 4 and 72 hours on average, causing disability, tiredness, and inability to think clearly or work productively, which adds to the burden of the disease. So, migraine is not just a headache.

Pages

Recommended Reading

Fremanezumab offers a safe and effective long-term treatment option for drug-resistant migraine
Migraine ICYMI
Galcanezumab effective for migraine prevention in women with menstrually related migraine
Migraine ICYMI
Prior onabotulinumtoxin-A improves subsequent anti-CGRP mAb response in chronic migraine
Migraine ICYMI
Comparative efficacy of anti-CGRP mAb in chronic and high-frequency episodic migraine
Migraine ICYMI
Galcanezumab and rimegepant offer effective options for prevention of episodic migraine
Migraine ICYMI
Galcanezumab and rimegepant offer effective options for prevention of episodic migraine
Migraine ICYMI
Fremanezumab benefits migraine patients with inadequate response to prior preventive medications
Migraine ICYMI
Commentary: Examining CGRP Antagonists for Migraine Relief, January 2024
Migraine ICYMI
Building a Toolkit for the Treatment of Acute Migraine
Migraine ICYMI
Retinal Perfusion Is Reduced During Migraine Attacks
Migraine ICYMI